格隆汇12月11日丨蓝帆医疗(002382.SZ)公布，公司心脑血管事业部子公司山东吉威医疗制品有限公司 自主研发和生产的三类医疗器械产品"冠状动脉刻痕球囊扩张导管"（简称"星痕™"）通过国家药品监督 管理局（NMPA）的审查，正式获得中华人民共和国医疗器械注册证。星痕™冠状动脉刻痕球囊扩张导 管具有独特的螺旋环绕三角刻痕丝，可实现360°高效压力聚焦扩张；作为市场上最高 4 根刻痕丝的冠脉 刻痕球囊，具有更大的刻痕面积，额定爆破压力（RBP）高达 20atm，可以提供更高的安全扩张空间， 在降低夹层发生率、优化血管准备方面表现卓越，对于钙化等高阻力复杂病变，其优势尤为显著，为冠 状动脉介入治疗提供了更安全、更理想的选择。 ...

Core Viewpoint - The company, Bluestar Medical (002382.SZ), has successfully obtained a medical device registration certificate from the National Medical Products Administration (NMPA) for its self-developed and produced Class III medical device, the "Coronary Artery Scoring Balloon Dilatation Catheter" Group 1 - The product is developed and manufactured by the company's subsidiary, Shandong Jiwei Medical Products Co., Ltd. [1] - The approval signifies a significant milestone for the company's cardiovascular division [1]

Core Viewpoint - Blue Sail Medical (002382.SZ) announced that its subsidiary, Shandong Jiwei Medical Products Co., Ltd., has successfully developed and produced a Class III medical device, the "Coronary Angioplasty Balloon Catheter," which has received the medical device registration certificate from the National Medical Products Administration (NMPA) [1] Group 1 - The product is categorized as a Class III medical device, indicating its high risk and the need for stringent regulatory oversight [1] - The approval from NMPA marks a significant milestone for the company in expanding its product offerings in the cardiovascular sector [1] - This development may enhance the company's competitive position in the medical device market, particularly in cardiovascular treatments [1]

证券代码：002382 证券简称：蓝帆医疗 公告编号：2025-097 债券代码：128108 债券简称：蓝帆转债 蓝帆医疗股份有限公司 中国 NMPA 注册的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 关于子公司冠状动脉刻痕球囊扩张导管获得 近日，蓝帆医疗股份有限公司（以下简称"公司"）接到通知，公司心脑血管事业 部子公司山东吉威医疗制品有限公司自主研发和生产的三类医疗器械产品"冠状动脉 刻痕球囊扩张导管"（以下简称"星痕™"）通过国家药品监督管理局（NMPA）的审查， 正式获得中华人民共和国医疗器械注册证。现将相关情况公告如下： 一、获批产品基本信息 产品名称：冠状动脉刻痕球囊扩张导管 注册人名称：山东吉威医疗制品有限公司 注册证编号：国械注准20253032515 星痕™冠状动脉刻痕球囊扩张导管的成功获批，不仅为临床处理复杂冠状动脉病 1 变提供了又一精准高效的预扩张选择，也标志着蓝帆医疗心脑血管事业部在构建"PCI 优化全链路解决方案"的战略拼图更加完整，在 PCI 治疗中进一步成功实现从简单到 复杂病变整体解决方案的"一站式"供应，预期将对 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-096 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于子公司为公司向银行申请授信提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、担保情况概述 限公司与浙商银行股份有限公司济南分行签订了《最高额抵押合同》，山东蓝帆新材料 有限公司为公司向浙商银行股份有限公司济南分行申请授信提供不动产抵押担保。 本次担保金额全部发生后未超过公司第六届董事会第十六次会议、2024年第三次 临时股东大会审议通过的2025年度公司及子公司申请授信及担保额度的金额范围，无 需另行召开董事会或股东会审议。 截至本公告发布之日，公司在2024年第三次临时股东大会批准范围内担保额度及 使用情况如下： 单位：万元人民币 | 新增担 | 是 | 被担保 | 本次担保 | 保额度 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | ...

Group 1 - The company plans to apply for a total credit limit of up to RMB 1.71 billion for 2025, which includes various types of financing such as working capital loans and bank guarantees [2] - The company will provide guarantees totaling up to RMB 1.71 billion, with RMB 1.544 billion allocated for subsidiaries with a debt-to-asset ratio below 70% and RMB 166 million for those above [2] - The guarantee period is valid for 12 months from the date of the shareholders' meeting resolution [2] Group 2 - The company's wholly-owned subsidiary, Shandong Lanfang New Materials Co., Ltd., has applied for a working capital loan of RMB 87.5 million from Industrial Bank Co., Ltd. [4] - A guarantee contract has been signed between the company and Industrial Bank for the loan, providing joint liability guarantee [4][9] - The total amount of guarantees provided by the company and its subsidiaries will not exceed RMB 3.341 billion, which is 40.81% of the company's audited net assets for 2024 [11]

证券日报网讯 12月5日晚间，蓝帆医疗发布公告称，近日公司为全资子公司山东蓝帆新材料有限公司向 兴业银行淄博分行申请8，750万元流动资金借款提供连带责任担保，本次担保后山东新材料担保余额升 至30，246万元，剩余可用担保额度82，789.77万元；截至公告日，公司及子公司担保最高额334， 114.31万元，占2024年度经审计净资产40.81%，无逾期担保。 （文章来源：证券日报） ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-095 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于公司为子公司向银行申请授信提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、担保情况概述 蓝帆医疗股份有限公司（以下简称"公司"）于2024年12月6日召开了第六届董事 会第十六次会议、2024年12月23日召开了2024年第三次临时股东大会，审议并通过了 《关于2025年度公司及子公司申请授信及担保额度预计的议案》，公司及子公司2025 年度拟向银行等金融机构申请综合授信总额不超过人民币17.10亿元，授信品种包括但 不限于流动资金贷款、保函、银行承兑汇票、国内信用证、国内保理、融资租赁等综 合授信业务（具体业务品种以相关金融机构审批为准），具体融资金额将视公司及子 公司生产运营对资金的需求来确定。公司及子公司将根据金融机构的授信要求为上述 综合授信提供担保额度总计不超过人民币17.10亿元，其中，预计为公司及资产负债率 70 ...

Core Viewpoint - Bluefan Medical (002382) has experienced a decline in stock price and financial performance, indicating potential challenges in the medical device industry [1][3]. Group 1: Stock Performance - As of December 4, 2025, Bluefan Medical's stock closed at 5.46 yuan, down 2.5% with a turnover rate of 0.86% and a trading volume of 85,600 hands, amounting to a total transaction value of 47.07 million yuan [1]. - The net outflow of main funds on December 4 was 6.0374 million yuan, accounting for 12.83% of the total transaction value, while retail investors saw a net inflow of 3.9286 million yuan, representing 8.35% of the total [1]. Group 2: Recent Fund Flow - Over the past five days, the stock has shown a consistent trend of net outflows from main funds, with the highest outflow recorded on December 2 at 12.9393 million yuan, which was 32.24% of the total transaction value [2]. - The net inflow from retail investors peaked on December 2 at 8.4658 million yuan, which was 21.09% of the total transaction value for that day [2]. Group 3: Financial Performance - For the first three quarters of 2025, Bluefan Medical reported a main revenue of 4.182 billion yuan, a year-on-year decrease of 10.15%, and a net profit attributable to shareholders of -286 million yuan, down 30.09% [3]. - The company's gross profit margin stands at 13.66%, significantly lower than the industry average of 51.22%, indicating a challenging competitive position [3]. - The company's total market capitalization is 5.499 billion yuan, with a net asset value of 9.707 billion yuan, ranking 63rd in the industry [3].

Core Viewpoint - Bluefan Medical (002382) has experienced a decline in stock price and financial performance, indicating potential challenges in the medical device industry [1][3]. Financial Performance - As of December 3, 2025, Bluefan Medical's stock closed at 5.6 yuan, down 0.71% with a trading volume of 69,300 shares and a turnover of 38.97 million yuan [1]. - The company reported a total revenue of 4.182 billion yuan for the first three quarters of 2025, a year-on-year decrease of 10.15% [3]. - The net profit attributable to shareholders was -286 million yuan, a decline of 30.09% year-on-year [3]. - The third quarter alone saw a revenue of 1.401 billion yuan, down 15.02% year-on-year, and a net profit of -151 million yuan, a staggering decline of 153.64% [3]. Market Position - Bluefan Medical's total market capitalization is 5.64 billion yuan, significantly lower than the industry average of 11.01 billion yuan, ranking 63rd out of 124 in the medical device sector [3]. - The company's net asset value stands at 9.707 billion yuan, which is above the industry average of 3.893 billion yuan, ranking 7th [3]. - The price-to-earnings ratio is -14.79, while the industry average is 60.46, indicating a negative earnings situation [3]. - The gross margin is 13.66%, significantly lower than the industry average of 51.22%, ranking 121st [3]. Capital Flow - On December 3, 2025, the net outflow of main funds was 3.1814 million yuan, accounting for 8.16% of the total turnover [1][2]. - Retail investors showed a net inflow of 5.2753 million yuan, representing 13.54% of the total turnover on the same day [1][2]. - Over the past five days, the trend shows a consistent outflow of main funds, with the highest outflow recorded on December 2 at 12.9393 million yuan [2].